<SEC-DOCUMENT>0001214659-18-002678.txt : 20180406
<SEC-HEADER>0001214659-18-002678.hdr.sgml : 20180406
<ACCEPTANCE-DATETIME>20180406141622
ACCESSION NUMBER:		0001214659-18-002678
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180406
DATE AS OF CHANGE:		20180406
EFFECTIVENESS DATE:		20180406

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		18742829

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mercy Investment Services, Inc.
		CENTRAL INDEX KEY:			0001699865
		IRS NUMBER:				263224636
		STATE OF INCORPORATION:			MO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		2039 NORTH GEYER ROAD
		CITY:			ST. LOUIS
		STATE:			MO
		ZIP:			63131
		BUSINESS PHONE:		314-909-4609

	MAIL ADDRESS:	
		STREET 1:		2039 NORTH GEYER ROAD
		CITY:			ST. LOUIS
		STATE:			MO
		ZIP:			63131
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>p46182px14a6g.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securex Filings LLC
    Document created using EDGARfilings PROfile 4.3.3.3
    Copyright 1995 - 2018 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: center"><img src="mis_logo.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">PROXY MEMORANDUM</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify">
<table id="z26e7c31eaf044da49073e4718374332f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 73.35pt; align: right">To:</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Pfizer Inc. Shareholders</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="zab04820cf02642e3a9d8122c9189ce77" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 73.35pt; align: right">Subject:</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Shareholder resolution to require the Chair of the Board of Directors, whenever possible, to be an independent member of the Board</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="zb0baf7ea4fd64623920b62716bf346ab" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 73.35pt; align: right">Date:</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">April 6, 2018</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="z777a43b5448b4a36ac57531d7e698d7e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 73.35pt; align: right">Contacts:</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Thomas McCaney at <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>tmccaney@osfphila.org</u></font></div>
</td>
</tr>
</table>
</div>

<div>
<table id="c3041cdc3ffe434faf6228330c4c78d8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 73.35pt; align: right"></td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Donna Meyer at <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>dmeyer@mercyinvestments.org</u></font></div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div>
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
&#160; <br>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify">We urge you to&#160;vote FOR Item 6, Shareholder Proposal Regarding Independent Chair Policy, at the annual meeting for Pfizer Inc. (NYSE:PFE) on April 26, 2018.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">This reform was recommended to Pfizer by the Investors for Opioid Accountability (IOA), a diverse coalition that includes state treasurers, publicly elected comptrollers, asset managers, faith-based, public and labor funds.&#160; We are members of the IOA, which was established in response to concerns for the threats to shareholder value stemming from the opioid crisis. &#160;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Independent board leadership is absolutely critical at this juncture of Pfizer&#8217;s business strategy:</div>

<div><br>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: justify">
<table id="z673125ecc7464f36a3ca6a793673e0f9" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; COLOR: #000000; WIDTH: 18pt; align: right">&#183;</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Pfizer faces mounting reputational risk related to its drug price increases</font> over several years, both for the opioid related treatment drug known as naloxone, but almost 100 other drugs.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="zdae07f767dd34e50bc3f6c174b3af08e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; COLOR: #000000; WIDTH: 18pt; align: right">&#183;</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Pfizer&#8217;s pricing strategy is particularly concerning when a significant portion of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Pfizer&#8217;s revenue and net income</font>, components of the metrics used to determine the company&#8217;s executive pay plan, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">have been shown to be derived from drug price increases alone.</font></div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="z2e48629ca36545ac8f20fd9967ca69e0" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; COLOR: #000000; WIDTH: 18pt; align: right">&#183;</td>
<td style="VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">The recent <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">$8 million retention award</font> to Pfizer&#8217;s CEO and Chair Ian Read, part of a total pay package of $27.9 million,<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">i</sup>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">represents a miscalculation of optics in the context of Pfizer&#8217;s price hikes and reflects on the Board&#8217;s poor CEO succession planning process.</font></div>
</td>
</tr>
</table>
</div>

<div>&#160;&#160;&#160; <br>
</div>
</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Against this context, we believe that adopting a policy to require an independent chair at Pfizer is even more critical.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><u>PFIZER&#8217;S PROBLEMATIC HISTORY OF DRUG PRICING ISSUES</u></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">Pfizer&#8217;s history of drug price increases is well documented.&#160; In fact, under CEO and Chair Ian Read&#8217;s leadership, the company increased the pricing of almost 100 drugs by an average of 20% in just the first half of 2017.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">ii</sup>&#160; These increases mirror price hikes by Pfizer from 2014-2016, ranging from an average of 8% to 10% approximately every six months during the three-year period.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">iii</sup></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">In the context of the opioids crisis, access to naloxone, a generic opioid overdose treatment drug, has become essential to first responders and public health officials, with naloxone pricing straining budgets of cities and towns nationwide.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">iv</sup>&#160; Yet, an independent study by the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">New England Journal of Medicine</font> has shown Pfizer increased the price of naloxone by 129% from 2012-2016, with little transparency to shareholders as to how these price increases have impacted issues like executive compensation.</div>
</div>

<div>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div>&#160;</div>

<div style="BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: justify">From 2012-2015, 33% of the Pfizer&#8217;s revenue was derived from price increases alone.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">v</sup>&#160; A <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Credit Suisse</font> report found that net price increases contributed to 100% of net income growth at Pfizer in 2016.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">vi</sup>&#160;&#160; We worry that these metrics have been used as part of Read&#8217;s compensation performance measures under both the company&#8217;s short- and long-term incentive plans.&#160; Despite witnessing the regulatory scrutiny and public backlash to similar drug price increases by Mylan and Valeant, the Board has continued to back and generously compensate Read&#8217;s reliance on increases in drug pricing as an artificial means to improve the company&#8217;s growth and performance.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000; TEXT-ALIGN: justify"><u>PFIZER&#8217;S RECENT CEO RETENTION AWARD AND SUCCESSION PLANNING CONCERNS</u></div>

<div><br>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">With unsuccessful attempts to sell Pfizer&#8217;s consumer business line and competition challenges to the company&#8217;s oncology franchises in the background, Pfizer recently announced that it awarded Read an $8 million retention bonus in order to retain the executive for an additional year of service.</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;COLOR: #000000">vii</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">&#160; This award represents a clear misstep in the Board&#8217;s oversight of CEO succession planning.&#160; </font>During the eight years of Read&#8217;s tenure, the Board should have been curating a pool of appropriate successors.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;viii</sup>&#160;&#160; Instead, it appears to have waited to implement a succession plan until the year of Read&#8217;s potential retirement.&#160; In light of the Board&#8217;s inadequate succession planning, we believe that the company would benefit from a more independent Board leadership structure.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The nature of the award itself also demonstrates a need for a more independent and objective evaluation of the company&#8217;s compensation packages by the Board going forward.&#160; The $8 million award contains a performance goal that lacks a sustained metric throughout the vesting period, instead allowing achievement during any of the five-year period.&#160; Additionally, Read&#8217;s $13 million long term incentive awards should be more than adequate to incentivize him for an additional year of service, which like his retention award, will continue to vest after his retirement.&#160; Lastly, the grant effectively operates as a backdoor severance package.&#160; Albert Bourla, now a director, has been promoted to a newly created position of COO in order to &#8220;enable Mr. Read to spend more time focusing on the company&#8217;s long term strategic goals.&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">ix</sup>&#160; Effectively, Read is being paid 61% more than the prior year with fewer responsibilities.</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">An independent Board Chairman is essential to critically evaluating management&#8217;s performance, ensuring pay is appropriately aligned based on management&#8217;s successes and failures, and preserving the Board&#8217;s fiduciary duties to shareholders.&#160; While some investors may believe that Pfizer&#8217;s Lead Independent Director&#8217;s duties are robust, this has<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000"> done little to address Pfizer&#8217;s succession planning process or the legacy of a CEO whose strategies appear to have left the company in such a complicated state that finding an adequate successor is now problematic.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000">Pfizer&#8217;s Ian Read serves both as CEO and Chair of the Company&#8217;s Board of Directors. We believe the combination of these two roles in a single person weakens a corporation&#8217;s governance structure.&#160; In our view, shareholders are best served by an independent Board Chair who can provide a balance of power between the CEO and the Board. The primary duty of a Board of Directors is to oversee the management of a company on behalf of shareholders. A combined CEO / Chair creates a potential conflict of interest, resulting in excessive management influence on the Board and weaker oversight of management. Chairing and overseeing the Board is a time intensive responsibility. A separate Chair also frees the CEO to manage the company and build effective business strategies. In light of these issues, we believe the Board would provide greater oversight of management with independent board leadership.&#160; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; COLOR: #000000">We therefore urge you to vote FOR Item 6.</font></div>

<div>&#160;&#160; <br>
<hr style="BORDER-TOP: 0px; HEIGHT: 1px; BORDER-RIGHT: 0px; BORDER-BOTTOM: 0px; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BORDER-LEFT: 0px; WIDTH: 2in; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="left" noshade="noshade">
</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">i</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Anders Melin, &#8220;Pfizer Lifts CEO&#8217;s Pay 61% to $27.9 Million with Retention Bonus,&#8221; Bloomberg, March 15, 2018, available at </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.bloomberg.com/news/articles/2018-03-15/pfizer-lifts-ceo-s-pay-61-to-27-9-million-with-retention-bonus</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">ii</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> David Crow, &#8220;Pfizer raises US prices of 91 drugs by 20% in 2017,&#8221; Financial Times, June 2, 2017, available at </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.ft.com/content/b2e0dd80-47ab-11e7-8519-9f94ee97d996</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>.</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">iii</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Ed Silverman, &#8220;Pfizer just raised drug prices by an average of nearly 9 percent,&#8221; STAT, June 9, 2017, available at </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.statnews.com/pharmalot/2016/06/09/pfizer-drug-prices-turing-valeant/</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">iv</sup> Esther Honig, &#8220;As Opioid Overdoses Bleed City&#8217;s Budget, Councilman Proposes Stopping treatment,&#8221; NPR, June 29, 2017.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">v</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Mathew Herper, &#8220;Pfizer&#8217;s CEO Faces the Drug Pricing Firestorm,&#8221; Forbes, October 13, 2015, Forbes, available at </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.forbes.com/sites/matthewherper/2015/10/13/why-viagra-keeps-going-up-pfizers-ceo-on-the-drug-pricing-controversy/#6bc1d4cc66af</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">vi</sup> Credit Suisse, Equity Research: Global Pharma and Biotech, April 18, 2017, p. 5</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">vii</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Arlene Weintraub, &#8220;Pfizer hands CEO massive pay raise &#8211; plus $8M bonus-to dissuade him from retiring, FiercePharma, March 16, 2018, </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">available at</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.fiercepharma.com/corporate/pfizer-hands-ceo-massive-pay-raise-plus-8m-share-bonus-to-dissuade-him-from-retiring</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">viii</sup><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #0563c1"><u>https://www.spencerstuart.com/research-and-insight/ceo-succession-planning-ceos-critical-role</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">ix</sup> Pfizer, DEF 14-A, Proxy Statement for 2018 Annual Meeting, p. 20.</div>

<div>&#160;</div>

<div>&#160;</div>

<div><br>
<hr style="BORDER-TOP: medium none; HEIGHT: 2px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000; MARGIN-RIGHT: auto" align="center" noshade="noshade">
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>mis_logo.jpg
<TEXT>
begin 644 mis_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!H17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    1    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XR,0  _]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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MD'[8G_AO_@K_ /1!4YO^#H__ ()_J<?\*A_;#/NO@#X*D?\ K076OX)-\/\
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M;_X*_P#T05'_ !%(?\$__P#HD'[8G_AO_@K_ /1!5_!715?\2W>&7_0+G/\
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M?EV&IJ$)6C[5PIU90:?P<R5D[']*J?"CX5XY^&OP_P"O?P;X<_\ E;7\@O\
MP=->$_"WA>3]BU?#/AK0/#HO4^/K7@T+1M.T@7;6TOPI6W-R-/MK<3F!9IEA
M,N\Q"64)M$C9_K4^(W[07P/^#^F2:Q\5?BQ\/OAWIT:NS7'C'Q;H6@\(GFML
MCO[Z&60^7\^V-';:1D \5_%[_P ''?[77[-?[4E_^RK9_L]_&+P;\6IOA^GQ
ME'C$^#;Z35(-!_X25OAG-HOVV[2%;53?)IMX8PDSL#&%8 L!5>!N$SB?B/PW
MBOJN9SP,98OVF(]ABY8:-\.XP]I4Y/9QO.45%R:U:L/QEQ&50X(S3#0K8".,
MFZ+HTH3P_MY*,XNHZ<8OG:4+<W+?1J^Z/YBJ***_T;IN\%K?=-[ZIM/[FK'\
M*2O=Z-:WU5M'JOO6H44458C_ %7/^"=__*/_ /89_P"S._V9?_5*^":*/^"=
M_P#RC_\ V&?^S._V9?\ U2O@FBO\C^(?^1_GG_8XS/\ ]3:Y_IWD7_(DR;_L
M59?_ .HE$^._^"^W_*)7]K#_ +H3_P"M+?!NO\V>O])C_@OM_P HE?VL/^Z$
M_P#K2WP;K_-GK^W?HM_\F_SC_LL<P_\ 5)P\?R%](W_DM\K_ .R5P/\ ZM\\
M"BBBOZ3/P$*_KK_X)R?\&_?[*G[4O[*'P6_:/^+_ ,4OCO-K7Q3\.7.O7/A3
MPEJ_@KPYX<T:6R\2ZII4-M93W_@;Q#K=Q&UMI43O(VHHIFN+E]J(T<<7\BE?
MTQ_\$ZO^"E/_  5Q^'WP2^&'P1_9S_8HB^/GPF\':?<:5X2\0R?!'XNK#<:/
M/KU[=W+2_%#1O$^D>!56/4-1O+5-0O(B$EM9TD*BUF _(/&B/&/^K&%J\%YQ
M0R?'T,THU<75KYA@\N6(P2HUU+#TZV-M1E-UW1J<O-"7+3<DW;E?ZAX4/AG^
MW\4N)\LKYGAI8&V$IT,%BL<Z6+>*PZ]K.EA(SJ*'L?:P<FN6\DF]4?7W[4O[
M"'_!!/\ X)Y^*O"/@W]I"Q^.-]XF\;Z#J7B'1+<ZYKNNSR:'97IT62[O;GP[
MIGA^WMA<77VF*&&!UFDCAE^T0QQ,GVAG[-W[:7_!N]^R9\1++XN_ WPK\0?"
MWQ%TC2-5TC3?$]UX:\=ZU<6%IK5J++4VM;/5=<N=-MY[NT\VW>6*S0+%<31H
MBHX5?T+TWX[_ /!4WXF:39ZQ\8_^",WP4\87.G0W$FG6WB3]I3X2:=J<)N3$
M;R&RTWQ3X6\=/ICW7E1R3)-J=JMQ)!"\\A,:@\I^RI^V_P"$_C;^VA_PQ)\<
MO^"5?A;]EWXE#P/XD\<RW'B63X=^-(?[)T&VMI;.\M+2Q^#_ (=LM6T#7FDN
MHM/\0:5KE[9BZL;J)MQ1]G\Q?7\]QV2YA2XAS+BSB&KE^#KUN)*61>(/"4L+
M]4IRJ2Q$I8"DI5)TWAN6%6E.59RG"5XZ\C_H".'R/"9M@?['P^0Y/+%XZC2R
MAYIP?G4:L<2W%4(K$U)Q4)RJ?#)\L8WO>-F?F/\ LK_\%@/V-/AM_P %'_\
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MV=];J[;UWU?4_E:HK3FM-)-:-M:.V[U?^844459!_JN?\$[_ /E'_P#L,_\
M9G?[,O\ ZI7P311_P3O_ .4?_P"PS_V9W^S+_P"J5\$T5_D?Q#_R/\\_['&9
M_P#J;7/].\B_Y$F3?]BK+_\ U$HGQW_P7V_Y1*_M8?\ ="?_ %I;X-U_FSU_
MI,?\%]O^42O[6'_="?\ UI;X-U_FSU_;OT6_^3?YQ_V6.8?^J3AX_D+Z1O\
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M2ZQTE).S2:>NRLW]A93_ ,/I?^"PPRJ :5^S/D_,0H'@"Q'J.!R>"OX=H/\
M@W"T30X?V-?C'XJT^QLQK?BC]KCXQOKFK+&IO;^/3;'P?#HUM<77S226^FV-
MPXL(&+1VJ7<JQ?+(2U']C.^72_\ @L9_P6CU!FS'IW@_]GC4&)Q]VU^&4%RQ
M+=",1\GZUSW_  ;":\NJ_L(_%BS.WS]/_:L^(%TX$GF'R]:^'GPFOT)'4!I/
M.*]!R>M?I_%M.4\@X[K0NHQP7@O3J]I0?"]9Q3UNU[10EKU2[(_.^%94Z>><
M'TIQBYRK^*,Z;<>;EG_;>73;C>_*VI25]^63C>S:/Z//+;GG.3GDG_"OY1_^
M#J&(Q? ']E-%)*#XP^+,EF8D[? LO1?N EBN" " &ZER:_J]K^4C_@ZE_P"2
M!?LJ_P#98?%__J"O7Q?@S2IQ\4N"ZB@N=9NH)OI&6&KN27:[A%^J1];XKMR\
M/N)H-OE66U*EEI>4)4XQOW24GIUOJ?Q+4445_IS15J4%K9*RNVW9-I:O?1'^
M>U72I-)62DU9!1116IF?ZKG_  3O_P"4?_[#/_9G?[,O_JE?!-%'_!.__E'_
M /L,_P#9G?[,O_JE?!-%?Y'\0_\ (_SS_L<9G_ZFUS_3O(O^1)DW_8JR_P#]
M1*)\=_\ !?;_ )1*_M8?]T)_]:6^#=?YL]?Z3'_!?;_E$K^UA_W0G_UI;X-U
M_FSU_;OT6_\ DW^<?]ECF'_JDX>/Y"^D;_R6^5_]DK@?_5OG@4445_29^ A7
M[A?LR_\ !?O]M#]E/X$_#C]GKX=> OV<=7\$?"[1;W1/#VH>+_"/Q$OO$EW:
MWFK:IJ[#6;O2?B=HVG3NESJD@$EGIEFI6.-3#\I+?A[28]S^G^%?.\2<*Y'Q
M9A:&#S[+J&98;#8CZS1I8B+E&%;V<Z7M%:4/>]G4G'?:3T/=R#B+-^&\36Q6
M3X_$9?7KT/J]6KAI1C.=+VD*GLVY0G[O/",M$O>BM3^C>3_@Y^_X*#S;!_PJ
MW]DDA'WD-X(^+(!^1TXV?&1?F&_<H;*94;A7S9\.?^"A_P 7?VRO^"LG[#_[
M2'QNTOP#X;\4:+\5/@?\)(M,^&ND:[I/AJ/PU=?$+4[&*XDM?$/B'Q+?OJ4D
MOQ U0WEPNH1VPB6W6&TC\EYKC\75P,Y).5('3@GOT[>E>C?"'QG#\.OBW\+O
MB)/'<26_P_\ B)X&\;/':*&OC'X7\5:5K=P]BA7RY[N.&Q9[:V=X5GE 0RQY
MW5\9/PMX-RG!YW6R/A["8+,L;D&;92L3AH?O>3,<)*E:-^>47SQIQ3YN76[L
MDVOK:/B+Q9F6-RBCFV>XS$Y=ALVR['N.*JOV7/@L52KN4FE"+45S/X4TEU>A
M_J#_ !=^$?PA^$?A#]L+]HSPWX*L=!^)GQ(^#_B'5_BCXTLI+UM4\6V_PO\
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MCZ@]H91<1V,4'Q4N)I;F)EN4F\A9)%DE5(OM&V''S1\6_P!@/]M7X%VMW?\
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MS(9)(I-CC?%(\;91F!_S^#\0_B".3XY\9 <\GQ-K8^ZI8_\ +[V568^B@D\
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M?NFY?'7C!XW$GS#Q/K3(RQ /+R+XJ1& &DZA  S8'-.?XA?$%<;_ !QXR7S
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MCSPS\6_A]\9?VE?C]XMUSX8?LO\ P$C@'B;Q!X:L+.\\4_$SQKJ4HDT/X4>
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MG"O=:A>S:D)KYD:97;SWQY^SM\1_A]HNA:_J,O@+Q-I_B3Q&_A+2S\./B?X
M^)5U)XC^QB\M])EL/!/B+6[^VNKW/V2P6>U7[;?$6]MYV&==#Q_^S+\3OAM9
MSW'B*7P)-?:=XOT/P%XC\/Z!\2?!'B+Q)X3\6>)+._O]'TGQ+I.DZY=2V/VV
MUTK442[A>[LHM0L[G3+FY@OK:Z@MS791ML]GTOK=W:ZMV:_#3V<LP^18/%X3
M'3\2\7FS64XO),M^NXCA^.6X6FL5E]&KBX4,OP6'AB<;AZN#AA:5?&QM3^L2
M@JCE5=_T%_;L^-/[(_QQ_9G_ &.?AC\*?C;?ZKXP_9(^$VO> -5M]>^%'Q!\
M.VOQ&NK[2O!5K:3>%]2N+*[L]&1[[PWJA,6OBTV0ZC#)++;)Y^'Z)^UQ^SQ^
MTY^P];?LT_MK>+?&'A_XU_ ?4;NZ_9@^/5KX:U?QPPT/4]/$,?@/Q?:^'[==
M2;P_IATO3]-O9KRWN)[[2&\/2VURNK:/J3M\GW'_  3U_:9MEDG?3OA,+%/&
MLWPW&HM^T/\  F*R?Q]!;6]W/X0C>7X@QRGQ!%;W$1?2I(([U9&$+P+)P/G:
M/X,?$6?X-W_Q\M= 2]^%^C^-;#X>Z[J]GK&BWFH>&_%.KVFIWVD6OB/0K;49
MM5TBQU2VTFY:RUF>W;2;J>:PM;:\FN+V*.C57]VU]U9[)^>MD]'KTUU/C\!P
M9X6O(\CRC+N.I8[_ %4XQQ.<<-9QA^)LKPV?Y7G?$F8X['X[+</BZ$$ZE#B'
M&8G&X+$Y/6A6PF*PTX8.K1E3<+?;7[ G[?=I^R;;?%/X/?%;P')\<OV5_C?I
MT^D_$SX8SZJ-,G@DDM;72+CQKX0=[-7?Q)?Z$LFGW6FW^H:(NJQV6A/-KGAS
M4=#M]4NCQU^S_P#\$Z/%&J7WB;X-?MXZI\/_  G>A9;7X??&_P#9W^*>H^-/
M#DC0[)H(_%'P^&N:%X@C$P6XM[>?3(F52T,FLA0 _P ;?#GX"_$OXJ>#OBI\
M0O".DZ=+X*^"VG:)JGQ'\1ZSX@T?P[I^A0^)=1FTG0+6+^W;O3[G5=4U74;>
M:"UTW2X+RY9897VY\A+CT7P;^QM\;O'7PHT/XWZ7#\.=,^&/B+Q1J'@C3?%'
MBOXQ?"WPA"?&&FPBYN?#5S:>)?%VF7]OJRVDD%^+3[-)(=/F6\&8J%=6O%-/
M573UUM=--.U[K1V;WNTK>YFF3<'Y3Q7G7$F3<>5^"<^SG'Y=EO%LLMQW#N)R
M[-LXPF68>&64LQR+B#+LRRRCGE3+.6HYX3"T,=/#R]IBZE5RA-<)\8=#^ 7A
MJ'1=$^#'C_QY\4=5@OM4F\6>._$?@:T^'/A>YM9%TQ-%T_P1X4?Q'XE\1S6U
MOY>KOJFL>*[K2M0O);FSCMO#NEPVK3ZA;_9EN/AYIGQM^'/BOXI?$!?AWX1\
M ^,_"?CRXU,^%/$'C"[U/_A%/%NAZU)HVE:7X8MY[N'4]1M;:9(+G4WMM,@D
MMTE:0S11XWM._9&^.NM>)OC5X*T3PUH^L^+_ -GS3_%.J_$[PUI?B_PQ=:Q9
M:3X,CA/B?6/#=H-463QII.DF=!=W?A8:H]LFU[F"$20B7R[PE\,?$OC3P]X]
M\4Z+=>&(])^&^C)X@\4?VOXO\-Z)J*:-/JNFZ#;:AI.E:KJ=KJ&MPW6MZQI&
ME6SZ9!<QS7FHVD4<C&4833ZIK?H^F_W=?Q/M*$\DQF19KDRXOAF-667?5<RS
M2.8Y;B,RI3XDA"672J0PE"G@\++%TZ_L,L]GAEAY4U0H*,9TY.?WO_P5,^,W
MP!_:=_:3\;_M'?!'XGS:_8^//^$&LI? >M^!/&?A;Q+H4OAKP39>%[_5+C4=
M2M)/#6I65U)HEM-:Q6FHK>VZ7K1M;A?,S^8;=NO3OUZGZU];:)^Q#^T)K_AQ
M?%5GI?PU@TE/!OA'X@:C_:_QW^"FAZCX>\)>/&T=/"6M^)M)UCQ]9:CX?M=8
M;Q#H,<+:I;VS"?4[:#:SN@;Y^^)'P]\5_"CQQXB^'?CBRL]/\5>%KU+'5[73
M]8TG7[%)9K6WOK>2TUC0[W4=*U"WN+.[MKF*XLKR>)DF +!PRC2G%M<CO9N[
M?5M;[]W?Y^AP>'_^J>1Y5EO O#G$E'.EPME<,NHX>MFV#Q^8X/+\%]6IX>A5
MEA^6I7AAZ5>A3A*I%RY)1J7Y6F?Z4'[!/_)C'[%__9IW[.G_ *I_P=11^P3_
M ,F,?L7_ /9IW[.G_JG_  =17B2TE)=I/\S_  /XS_Y+#BS_ +*7/?\ U:8H
M^3_^"XN?^'7'[3^,Y_XLKT_[.'^$M?Q7_P#!.S2]3U#]LSX%2:?I^HWR:=XC
MUJ]OY+*UN9X+&S'@SQ+;F\U">")X]/M?/G@MH[RY80B[N;:(QS/(B5_:?_P7
M&.W_ ()<?M/GIC_A2O\ ZT/\):_SUS&MW)%;K&TCSLRQQIEGD<(\A2-<9=_+
M1V"(&8K&[8(5J[L)\#\IO\H^I_IK]"S*:F?_ $>?$3(H8JE@_P"V>,.+\JCB
MZM)58X2>9<$<)818B5-XBBZRBJMU%*]/DE-25W;ZG^!GB'XO?"7X?_$?XC?#
MA?%?AWQ+\,_&?P7NA?V]EKD%SH-U#J'C-=7TW6;??;B.WGMGBA\4:?JT,%E<
M:3/>66JZ6+:^MKIOHC]H/P/\+/$7[/7BW]JOX*:IX-\/>$/C)\3?A]IWC3X!
MZ'>Q_P!L_L^?$W2;;QM=ZOX9L+)Y;>67X=^*-FM>,?AOJ<FFI/::?J-UH>H.
MD^G0PP_F4]NA:'=;7 >$R;$$4I<;&RWF(L9>$)E=YF$80O'NQO3-I]\91'CE
M4S2>5&/*E(DES& J'8=V]I$CCVDK))N2,LZ2*O4GHTU=--+6UI7O=:6?9IWN
MF]G9K^L<PX"IXS.<#G^'SW"Y=CJ><97CL=3PV7PE2S?(\M>3U:N79A3GBDO:
M1Q&4_P!I99FW)4EEWUG&4,+.,*^)IXC]-OV<TO/VE/V7M3^%7CS6]+73?V+/
M'T/[2%@?$VLV\#ZE\!_%3S6O[0/P]T=9]B;[KQ-I_A+7-(L;(3PZKK/B.[MK
MB./^T)DN^6_8#\1>*?BA_P % _ OQ#\26%_XKUS7_$/Q)\>>*Y%BOY-]UJO@
M3QW>:C)>W-A&?L=A/<70TV&>-=,2#_1[6P41K%:I^>Q5E9$96#/'*ZK@XV1*
MSRONQA418V+NS!4R@8@R1AJKVS3-F2&X4'E"8)@&.3N4$QX)B53)<CK:P$7%
MR(H&$A&[\NCNDO5]5TNM-M]"9\!X3$8#Q"RZEG=+"83C'"9OA,GI?4E5_L)9
MW%KB3%4^?'8.%6CF^9UO[=G[+$X?E5.%92]JJ=0^V?$[^(5N/@!XD^'G[-6J
M_ 7Q/X4^+NA6-M?ZR_BQM*\=^.]9U_0-=^'<44WC^W_MZYB\+WG@_48;M;::
M;2=+75]+NK9+675+FZ/N/Q_U3X*_%WX(?%7XB:Q^RS/^QE\<?!/B?P/?Z8?#
MNO>.[#P9\9O%7C;Q7-;>+=!M/AY\0-%:Y\/Z[X;LCJOBN^O-$UVXBTNV2ZEU
MJ!+/Q#HUW=?EI#%%EBEN'#;HSYB!]H#*"R*S(=^[[C)O+1[G560.RW$BEG9(
MX1-=$[UC$6^Y940 EBL:;HK=&=?WKJ(,RQ_O#YR!CFTM;1WT;6]EKHE_P1XO
MPZPZK9#BH9_B,%6X<Q//#$X7&9UA\:L!B<ZIY[7P68\_$E>.;X+$K#1H^PSF
MGF<<)#&1AA/JL+^T^V9-+\0'_@G)I.J+:ZI-:C]M?6+ZYOUM[T+#:_\ "C]'
MLO[5:[_>I! NIVRVD^JS.;5-4>738O,O[=],3V+]B'X@_P#"M/AMXC\.>/='
MGU#]G_\ :1^(0_9Y^*EQ?6DL'A_2]*\:^#ET;0_'"7%UITVE2:C\*/%5QH7C
M6WW7D2K%H6HV%CJ-C<WQBD_+H6_^DS2+#(9X@8W '41LD9>,?\ME5F&6A\Q=
MN7)V!F$30".1I!NWE%9XN3*D;8/FM"!YJ1+A_-E91'#Y-QYK)]FG\LN]&M+)
M+UTUVMOU6^NM]19EX?8?.,NS;*\1FV$HX;.>),7Q XPP:I8C!4:U&$</4HU8
M8SVL\9@*M)YC@L?%Q5'%TXS52DIRFOV7F\ >*_A5^RU^W=^RY!>6?BI/@[X*
M^#UQXXN_ 2W&K^#]2^,VN_M%_#G7/&5SHNJ6>F/%K-YX0\(:)X6\+W[13Z@U
MFGA'4]2%O86$]Q<SW_AE-9V'_!+KX2RZY^S[J?Q_LF_;T\<^(9_#]JGCE+F+
M1X?@YX)M9[VQM/"B)<7ECJ-Q;W_AB)]6BO\ PY+=M+8S3+A8T_%VXL6CEA^U
MV[QR1^:\7F8C,9CSYA97 /RE0&S]UGA5L-/ LD9MXI/G>)@XZ '/;!P%]L_Y
MP*ISYE%-?##D]??<[[=FU9I[)W?3QZ7A14Q5&M+$\62Q$ZW&W#7&N)S&.#KX
M6ICL?E>15<HQSK2P6>82="OFN*E/,:7U?%-4:%2& E'EA9_8G@#2/CC\ ?&W
MQ[\0:?#XG\+?$SX5^ O!VO7^KZ"^IW=UX6\0M\:_@;XA:WU75=,L9D@GDL[I
MQKFGWS21RVR>*+74;*72HKYHOHOXS>%OAQ\8O@S\:OVS?@]IOP^^%^C^*_"G
MA7X=_&K]G/0-:L([_P"'7Q4_X7'\$]1C\7>%M&3[///\-_B;9:-J6NV)_LR6
M+P]XIN=>T6[,]LMM]F_*_P"QQ%O]3(2H<@C)3B,N59P/+5R%Q&A</*W[N)6D
M^6K"#^$J4*Q^80<[?+8N$=)!\DBR!0T31LPD5XF0LDT1>5*R:M=.^CZ/HT^_
M1Z:K31V:]NOP!3Q&=8/B3!9[#!8W"X[)*%;$T,LNLUR'"T,C^LY!FF$EF$Z4
MHYCBLH>,RG,9XE8S*ZTW[#G56NJWUU^S]HOB36_@)^VIJ*:/KVKV\?P2^%5H
MM[_8VK30LVE?M+_ JZAL(KJ.WODEFTS0;)+^ZTJ"4FP\/V'VMK>TTR'97R5+
M/<W+B6[N;B]N##;*]W=RM<74ZI:PK"\\[8\YQ (D#@!-BHJ#8JU5BM#<RB6W
M2220Q^845'S''L+L9@5!@:-%=YDF\MX%24S*@BDVRA&0LCJ597964C!#(Q1@
M?HRD>^,C((-',]+-JRMI=7U;_4^IRG(WEN<\4YK+%X>N\^QV6XB&&AAX4:F"
MIX/*,/EDZ<9K$5G6A5>7TJTI1HX9/GI.49^ZW_IL?L$_\F,?L7_]FG?LZ?\
MJG_!U%'[!/\ R8Q^Q?\ ]FG?LZ?^J?\ !U%>-+=^K_,_Y[^,_P#DL.+/^RES
MW_U:8H^3/^"Y'_*+;]J#_NBG_K1'PDK^*G]BWQ?H?A#4?C:?$O@WXMZWH?B?
MX/W/A#4?''P*CTZX^*GPH@UCQMX/D3Q9X=L]0ELDO+2]N+&'P[KD-MK7A^]3
M2]5FG@UJS,+;_P"UC_@N,-W_  2X_:?&,Y_X4K_ZT/\ "6O\]I49264%6("[
ME;:V!)'* &!# >9%&Y (R47.0*]+!)^SD]/XC333=_=BOY6NN^ZULUN?Z>_0
MBR>CG_@)QAE=6I7HSK>).;_5ZU"K5HNG6CP[P)7A5E.C6I2_<SPT'&$X5Z-6
M,ZD*U*4+QG^EGP=3Q%X5_P""CGPWM](^(OQ#\>F\\0_#^\U?QG<Z*_A_XA7_
M (6UWX2>$_$-WI?Q!T+2O$.K6FG^-/"&EW,'AKQ=:3>(M0L[3QAHQM[C5XI_
M,C7PKXWZ[\2+^X^"$EUXD^/^NZ-H%AJ.E^#=9^-5I?Z7X[G\86^N6>I>++?1
MEDU+5[R[T:)K[PC%IDD>MZM%<70N8;;[%.R:8_R.\(==A7" ,%1#Y<<8?=N$
M*1E4AR&V?N@F(U2,8CCC56I;Q0\Q00PKLBCVPQ111[(':2V3RHU6/9;2,&MU
MV[;?RX?)""W@\OJY6TTFM6VDN?KRZ:KR7Q/U>C/[ PG".,I9G1S+%9HL3*.0
MY1D==SPD85:LLLR_,,!4S'GPTZ,*57&_VC/$8C#X;#TJ<)THTZ4E%1<?VM_X
M*0S7^KQ_M-0^&_'7BSXIZ:O[:7B:_P#B+X;\627$D_[.#^'+OQ_I_P .XO >
MCW=[KMK8?"_XLZ!XC<2_$&PN?#^CZGJ/AS2_"<NAI)]BUF?Q?2_B5H'Q$^!'
MP)_: UCQ9K&E?$O]B;2?$WPT\01RZ[J=MK'CN[UJYU_Q3^R?=>&(?-9KYM,U
MVY\2>'OB/)$EQ,G@+P7;W6K/)%>6MC9_EQ%:P6\:0P1+$D"@1F,LLBX@2!6\
M[=YQ9(HT"2%S)&T:2HRRHKB:14DEEED4.\ID=R54C>S,QD1,>7$X#2Q1O$J/
M'!-<6T92WN)HY+FW><H2A6=IWA3;G)*$X>_'1-)R<4I)IM7C[J?*?.95X5U<
M!PUDV1O.G4J9=F%7$U,P673PD\9EV*PE#+,SRC$Q5>5-T<;ERK4:<Z=.FZ"6
M$J5(8K%82.*J_?G['VI^,6^%/_!0>[TW6-=N+Z[_ &4+74+J>"XU&:ZN]7OO
MCY\)1J5VS^;.&UF;0[WQ4F^60:C%I4FI2QQK9+-'%GV-EXLL_P!COX6ZQ\ 7
M\4KXHU#XL_%NT_: O?A?<>(9/B#]HTZS\$M\&X?'+>"KA_$"_#:V\)3^+7\*
M)J5]!X2;Q+=^)Y"L?B*6,2?"'V>$NKF(,ZERKL%9RKJP*.SY:2-?-?9'(6CC
M+;HU5@")_FWK(&D5T#*C(_EF-7V[TCV%1&C%(RR)M1FCB8J6C0K*C.4(^Y)I
MPLM)7C>:E9^[HU=IK5?$[GMXK@FJ\\QN;T,VPDXU<_R'/*&"Q& E5P=:GDV0
MXG(IY?F-&.*2KT,1'$+&1E"2]EB,/23A53<X_H[^QAXY^+?B7]N'1_$?Q!U/
MXB1>,KKX;?$O2_&VIB#6+?Q@^E>'_P!GKQ9IFC7NLI(^FWFIZM+'I?AI+"^U
MV9#K?B.^MM1O[T:A?33#S'Q'X@\3V_QI_9IUKQ*OQN^+UEX9U[PA<Z!HWQU5
M+;X@>,7TWXI_VWJWA/3WU/6O%<JZ9J5S-'IFA&SUC6%:[>[=;>:.RFTJ7XJ^
MS0! GD)L4 *@50B@+L 5 0JKY>(MJ@+Y21Q8\N.-5:D$$'F&.")3,I67='&Y
MFX<!I2X8R.HD<K(^9%8AE8%012A5FE%QE=RE+FDI-/F4+W5GK>*ULV[V>QUT
M^!:/]LYCFW]HX*%/,>'J.2?4:."JX*EA_J^$S'#0GA\3A<;'$8>-7Z]:4L/R
M5:/*W2?,S[X_:ST33+[P/\)O%7@CXL?'?QMH'B'QM\4M+TSX6?M*>']+T?XP
M^"-82'X:WNJZSIT^A^*?%::UX5\4W^NV6F:;JR67@Y_^$G\.:Q9VNDVT+WIT
MGXDO](\4^&/$<FA:CI>L>'O&.AZNMM<Z1=6UWI_B'2=<T^]@:WL_L6V#4;?5
M8[D01"(QQSV]\52&*\V#S*^D:SJ'A[6]+\1:3-!:ZSHNIZ?K6F:@\:>=;:EI
M4L$^FW/F%"TQLY84DMH+CS;:%WN"D2_:KKSLUT,K,\K2S2R>87>:625G,TKS
M3.[2.Q>2:=VEED8EY)#YCLS@$1R.4YKE]GR1YOWCY8222O&#E[TI/?LEI?J=
M>1</8_)LG61XG,X9E1CA,PH1QU:C"%:4\57K?5*<J5"%&C5P^!PE2E3F[0JX
MNI'VM>7MO:5ZWZW_ +8VO_$#0O\ @K=J.M^%=2U6'Q-H?COX(7?AVZMY+ZXE
M&FVO@;X<W%Y':6TUQ<1WVB>;!K0U&SF%QI%U/+J%MJ4=S$UQ:5Y-XK&F?$;X
M4?'']IOX1:AX;^&<^M>!M#\+?M&_ _PUKU]X;OM'^)GB/XO>"7O?B/X7\&F=
MH;GX6_$B,W.H7:Z>\A^'_CJ[UOPD+.XTYM O-0_...RM(HY+>*U@CA>3SC$D
M421),3*XFC50!#,CSS.DL(1T:1F1@3FK#EF18W9@BR&9(E8JB3;8D$JHI"I(
MOV>%DD7#QR11RQE9%##5PE.4Y.5*TVYN]56@YI22O_,E*S6M]5NDUX&%\/IT
M,/PNJ6=2H9CP[E^1Y75JX7"M4\SRW+<5#$8[+J]">(Y(4<>J5"="LN?$Y=C8
M0Q-.56$)X>O]X3I\9--_99^!.M? .?Q7%H%]J_CF;XPWOPJDO/\ A,X?C!9^
M-O$D?A=?B"GA.6X\7:;HB_"23X?3> C?3-X:U#49?%9CCEU>'Y_C_P"(GB?Q
MCXS\<^*?%7Q":\D\;ZYJTU[XGFU&P&FZA-JA2.*22\M!;VJI<&**%7VPK]T
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MXOW'AWP#\))3I?B_S[;4+ZP^(NK2V-A#H.B+:37UR/D%OVPO@""0G_!/;X'
M$EL#XY_M92X+_.P:7_A<^7<,Q#MSE@>6/S'X>\2^*?$GC+6K_P 2>+->UCQ/
MXAU643ZIKWB/5=2U_6]3N/+CB:XU#6-9N[_5+Z=XXD4O=7DPCP! D**$&"
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>%P]'#4Y5&G.4*%.-*#FXQC%S<8IR<8Q3=[12T/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
